

REGISTER [HERE](#)

Biosimilars: The Next Frontier

Two-Part Webinar Series

August 12 & 13, 2020, 11:00 am – 2:00 pm PT

The launch of biosimilars in the US introduces competition to a trending specialty drug marketplace. Biosimilars are approved by the FDA for safety and are certified for “having no meaningful clinical difference” from their reference drugs. The nature of biologics makes it impossible to manufacture exact duplicates, as is the case with generics. Biosimilars is as much like a reference product as are distinct batches of the reference product! With savings estimated at \$54 billion¹ over ten years, we must address the market failures that are inhibiting adoption.

To accommodate current COVID-19 travel limitations, we have restructured this daylong symposium into two segments:

Welcome & Introduction to Biosimilar Webinar Series		Kelly McDevitt
Wednesday, August 12, 2020	11:00-12:00 pm	<p>Juliana Reed, MS, Vice President, Global Corporate Affairs Lead, Pfizer</p> <p>Wayne Winegarden, PhD, Sr Fellow & Director, Center for Medical Economics and innovation, Pacific Research Institute; Partner, Capital Economic Advisors</p>
	<p>Biosimilars: the big picture, the opportunity, the pipeline</p> <ul style="list-style-type: none"> • Overview of the landscape for biologics and biosimilars, key market trends and future issues for employers and manufacturers. • Opportunities for biosimilar adoption and key factors to consider in the effective use of biosimilars for employers. <p><i>Moderator: Kelly McDevitt</i></p>	
	<p>12:00 – 12:10 pm BREAK</p>	
	12:10-12:45 pm	<p>Lucy Langer, MD Medical Director, Practice Solutions, The US Oncology Network</p>
<p>12:45-1:45 pm</p>		<p>Sponsor Slides/Acknowledgement</p>
	<p>Melissa Mantong, PharmD, MS, FCSHP, Pharmaceutical Consultant II, CalPERS Health Policy and Benefits Branch Clinical Policy and Programs Section</p> <p>Ladd Carman, BPharm, Director, Specialty Pharmacy Services, Costco</p> <p>Bill Dinger, MBA, CPA Director, Healthcare Innovation & Labor, The Walt Disney Company</p>	<p>Biosimilars and Cancer</p> <ul style="list-style-type: none"> • Aligning incentives in Bundled Payment/CMS Oncology Care First Model <p><i>Moderator: Anne Ladd</i></p>
	<p>Benefit Design Strategies to Optimize Access and Affordability</p> <ul style="list-style-type: none"> • Purchasers will discuss how they have made decisions about the use of biosimilars in their pharmacy plan design. • Key considerations in balancing the use of biosimilars and biologics. <p><i>Moderator: Anne Ladd</i></p>	
<p>1:45-2:00 pm Wrap-Up Day 1</p>		<p>Lauren Vela</p>
<p>General Discussion and Q&A</p>		

¹ *<https://www.rand.org/pubs/periodicals/health-quarterly/issues/v7/n4/03.html>

Welcome to Day 2, Recap of Day 1		Lauren Vela	
Thursday, August 13, 2020	11:00-11:50 am	<p>Kimberly Tsaj, PharmD, CSP Clinical Pharmacist Supervisor, MemorialCare Medical Foundation</p> <p>Megan McIntyre, PharmD, MHA, Pharmacist Advisor, Benefits & Revenue Cycle, Virginia Mason Medical Center</p>	<p>Provider Strategies to Manage Total Cost of Care</p> <ul style="list-style-type: none"> Lessons from the field for purchasers. What are the issues with traditional cost plus reimbursement? How can purchasers help providers make high quality, cost-effective choices, including site of care? <p><i>Moderator: Lauren Vela</i></p>
	11:50 am – 12:00 pm BREAK		Sponsor Slides/Acknowledgement
	12:00-12:35 pm	<p>Sameer Awsare, MD Associate Executive Director, The Permanente Medical Group</p>	<p>Case Study in Value-Based Care</p> <ul style="list-style-type: none"> Kaiser’s overall prescription drug management strategy. Case study of an evidence-based approach to adoption of biosimilars. <p><i>Moderator: Kelly McDevitt</i></p>
	12:35-1:10 pm	<p>Heather Sundar, PharmD, Executive Vice President of Medical Management at Archimedes, Inc.</p>	<p>Quantifying the Biosimilar Opportunity and Making Data-Driven Decisions</p> <ul style="list-style-type: none"> How our intermediaries can help us and what the data tells us <p><i>Moderator: Kelly McDevitt</i></p>
	1:10-1:45 pm	<p>Brian Gifford, PhD, Director, Research and Analytics, Integrated Benefits Institute</p> <p>Rob Paczkowski, CEBS Senior Director, Global Benefits, eBay</p>	<p>Impacting Workplace Productivity by Optimizing Affordability and Access</p> <ul style="list-style-type: none"> Rheumatoid Arthritis: Opportunities and impact Measuring value by integrating the impact of adherence on lost worktime and lost productivity <p><i>Moderator: Emma Hoo</i></p>
1:45-2:00 pm Wrap-Up Day 2		Kelly McDevitt	
General Discussion and Q&A			

This program has been jointly developed by the Pacific Business Group on Health and Integrated Benefits Institute, with thanks to Program Sponsors

PLATINUM



GOLD

